Figure S1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, S. Peter Kang et al.|Unknown|2023Cited by 0
Supplementary Tables S1-2, Figure 1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, S. Peter Kang et al.|Unknown|2023Cited by 0
Figure Legends from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Unknown|2023Cited by 0
Table S1 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Unknown|2023Cited by 0
Table S2 from Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Unknown|2023Cited by 0